Autopsy report · NCT00533390

Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg

“Lack of financial support and low inclusion rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months after it had already started.
• Ran for about 5 years 9 months before it stopped.
• 130 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Oswaldo Cruz Foundation

Sponsor type

University, hospital or other

Conditions

Tuberculosis; HIV Infections

Interventions

efavirenz

Participants

130

Sites

2

Countries

Brazil

Trials that died the same way

• Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)
  “Poor inclusion rate \& lack of funding” (86% match in meaning)
• Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
  “Lack of financial support” (78% match in meaning)
• Impact of Surgical Theater's Patient Engagement
  “Lack of support/funding” (72% match in meaning)
• Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure
  “Poor inclusion rate.” (72% match in meaning)
• Effects of Empowerment-based Program on Post-discharge Glycemic Control, and Foot Ulcer
  “Lack of financial resources” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.